See more : Sono Group N.V. (SEV) Income Statement Analysis – Financial Results
Complete financial analysis of MustGrow Biologics Corp. (MGROF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MustGrow Biologics Corp., a leading company in the Agricultural Inputs industry within the Basic Materials sector.
- Apollo Hospitals Enterprise Limited (APOLLOHOSP.NS) Income Statement Analysis – Financial Results
- Jyoti CNC Automation Limited (JYOTICNC.NS) Income Statement Analysis – Financial Results
- Aroa Biosurgery Limited (ARX.AX) Income Statement Analysis – Financial Results
- SiriusPoint Ltd. (SPNT-PB) Income Statement Analysis – Financial Results
- Sun Corporation (6736.T) Income Statement Analysis – Financial Results
MustGrow Biologics Corp. (MGROF)
About MustGrow Biologics Corp.
MustGrow Biologics Corp., an agricultural biotech company, focuses om development and commercialization of natural biopesticide, biofumigants, and bioherbicides derived from mustard seed. It provides preplant soil biofumigation, a technology to treat soil-borne diseases and pests for various crops, including fruit, vegetables, and other crops. The company is also developing bioherbicide to treat unwanted plant growth for use in organic agriculture, home, and garden markets, as well as agriculture markets; and postharvest food preservation, an application in sprout, disease, and pathogen treatment for storage and food preservation markets. In addition, it focuses on providing CannaPM, an active ingredient to treat fungal soil diseases, as well as foliar diseases. The company was formerly known as Duport Capital Ltd. and changed its name to MustGrow Biologics Corp. in March 2018. MustGrow Biologics Corp. was incorporated in 2014 and is headquartered in Saskatoon, Canada.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
---|---|---|---|---|---|---|---|---|---|
Revenue | 4.71M | 6.48K | 12.87K | 0.00 | 0.00 | 2.00K | 2.10K | 109.02K | 12.42K |
Cost of Revenue | 384.69K | 298.21K | 203.59K | 187.68K | 74.19K | 44.74K | 48.71K | 21.26K | 75.80K |
Gross Profit | 4.33M | -291.73K | -190.72K | -187.68K | -74.19K | -42.74K | -46.60K | 87.76K | -63.38K |
Gross Profit Ratio | 91.84% | -4,502.72% | -1,482.03% | 0.00% | 0.00% | -2,136.90% | -2,217.13% | 80.50% | -510.45% |
Research & Development | 857.07K | 475.86K | 458.38K | 149.25K | 83.00K | 13.54K | 749.00 | 21.26K | 75.80K |
General & Administrative | 3.12M | 4.52M | 2.00M | 2.96M | 1.35M | 1.84M | 36.45K | 20.44K | 491.92K |
Selling & Marketing | 558.60K | 696.82K | 567.93K | 263.55K | 36.47K | 9.49K | 0.00 | 0.00 | 0.00 |
SG&A | 3.68M | 5.22M | 2.57M | 3.22M | 1.39M | 1.84M | 36.45K | 20.44K | 491.92K |
Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | 4.54M | 5.69M | 3.02M | 3.37M | 1.47M | 1.86M | 36.45K | 20.44K | 519.35K |
Cost & Expenses | 4.92M | 5.69M | 3.02M | 3.37M | 1.47M | 1.86M | 36.45K | 20.44K | 595.15K |
Interest Income | 211.60K | 103.55K | 3.32K | 45.87K | 45.88K | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 0.00 | 10.07K | 52.77K | 45.87K | 45.88K | 40.24K | 27.31K | 0.00 | 0.00 |
Depreciation & Amortization | -466.01K | 5.25M | 2.73M | 3.20M | 1.35M | 892.64K | 1.08K | 1.08K | 2.31K |
EBITDA | -676.94K | 0.00 | 0.00 | 0.00 | 0.00 | -1.85M | -170.25K | -147.89K | -555.31K |
EBITDA Ratio | -14.37% | -86,148.73% | -23,398.17% | 0.00% | 0.00% | -92,656.85% | -1,734.11% | -18.75% | -4,472.14% |
Operating Income | -210.93K | -5.58M | -3.01M | -3.37M | -1.47M | -1.85M | -36.45K | -20.44K | -557.62K |
Operating Income Ratio | -4.48% | -86,148.73% | -23,398.17% | 0.00% | 0.00% | -92,656.85% | -1,734.11% | -18.75% | -4,490.77% |
Total Other Income/Expenses | -466.01K | -313.51K | -334.69K | -109.90K | -164.09K | -40.24K | 250.74K | 108.35K | -25.12K |
Income Before Tax | -676.94K | -5.57M | -3.06M | -3.31M | -1.52M | -1.89M | -36.45K | -20.44K | -582.73K |
Income Before Tax Ratio | -14.37% | -85,905.87% | -23,808.18% | 0.00% | 0.00% | -94,668.85% | -1,734.11% | -18.75% | -4,693.03% |
Income Tax Expense | 0.00 | -5.24M | -2.73M | -3.15M | -1.35M | -161.14K | 88.55K | -24.40K | 0.00 |
Net Income | -676.94K | -5.57M | -3.06M | -3.31M | -1.52M | -1.89M | -36.45K | -20.44K | -582.73K |
Net Income Ratio | -14.37% | -85,905.87% | -23,808.18% | 0.00% | 0.00% | -94,668.85% | -1,734.11% | -18.75% | -4,693.03% |
EPS | -0.01 | -0.11 | -0.07 | -0.09 | -0.06 | -0.08 | 0.00 | 0.00 | -0.03 |
EPS Diluted | -0.01 | -0.11 | -0.07 | -0.09 | -0.06 | -0.08 | 0.00 | 0.00 | -0.03 |
Weighted Avg Shares Out | 49.90M | 49.01M | 43.74M | 37.31M | 25.29M | 24.99M | 24.99M | 24.99M | 20.91M |
Weighted Avg Shares Out (Dil) | 49.89M | 49.01M | 43.74M | 37.31M | 25.29M | 24.99M | 24.99M | 24.99M | 20.91M |
MustGrow secures Florida registration for biofertility product TerraSante
MustGrow Receives Florida Registration for TerraSante(TM) Biofertility Product
MustGrow Announces Grant of RSUs and DSUs
MustGrow's Arizona approval for TerraSante creates ‘double-dip' revenue opportunity, analysts believe
MustGrow secures Arizona registration for biofertility product TerraSante
MustGrow Receives Arizona Registration for TerraSante(TM) Biofertility Product
MustGrow wins registration approval for TerraSante in Idaho
MustGrow Receives Idaho Registration and Organic Approval for TerraSante(TM) Biofertility Product
MustGrow Biologics boosts TerraSante sales efforts in California
MustGrow Accelerates California Sales and Marketing Efforts for TerraSante(TM) Biofertility Product
Source: https://incomestatements.info
Category: Stock Reports